ClinicalTrials.gg
CompletedNCT06922643Updated Jun 29, 2025Results posted

Study of the Efficacy and Safety of Pegnano Plus Barivir (Ribavirin) in Treatment-naïve Patients With Chronic Hepatitis C at KienGiang General Hospital

A Phase 4 interventional study of Peginterferon Alfa-2A and Ribavirin Oral Product in Chronic Hepatitis C, sponsored by Nanogen Pharmaceutical Biotechnology Joint Stock Company. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-06-29.

Sponsored by Nanogen Pharmaceutical Biotechnology Joint Stock Company · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 14 years 1 month after the study started (first participant enrolled Mar 2011, registered Apr 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2a · Hepatitis C, Chronic.

Enrollment
47th of 83
100 · median 129
Started
2011
with 6 others
Phase 4
48 of 83
none open now
Registered
83rd of 83
by date

Among the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic, this one is the 47th largest by enrollment, is one of 7 that started in 2011, is one of 48 in phase 4, and was the 83rd registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About peginterferon alfa-2a

peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic as a file.
02

Study summary

This study presents a clinical study on the efficacy and safety of Pegnano combined with Barivir (Ribavirin) in treating treatment-naïve patients with Chronic Hepatitis C at Kien Giang General Hospital. The study aims to provide affordable treatment options while evaluating the virological response and side effects associated with the therapy

Read the detailed description

This study evaluates the efficacy and safety of Pegnano (Peginterferon alfa-2a) combined with Barivir (Ribavirin) in treatment-naïve patients with chronic hepatitis C (HCV). Conducted at Kien Giang General Hospital from March 2011 to March 2013, this uncontrolled clinical trial enrolled 100 outpatients aged 18-65 with HCV RNA >80 IU/mL and compensated liver disease. Patients received Pegnano (180 mcg, subcutaneous, weekly) and Barivir (15 mg/kg daily, oral) for 24 weeks (genotypes 2, 3) or 48 weeks (genotypes 1, 4, 5, 6), with possible extension to 72 weeks for genotype 1 with late virological response. The primary goal is to assess virological responses (rapid, early, end-of-treatment, and sustained at 24 weeks) by genotype and IL28B rs12979860 polymorphism, alongside safety through adverse event monitoring. Efficacy is measured via HCV RNA levels using real-time PCR, while safety is evaluated through clinical and paraclinical assessments every 4 weeks. The study aims to provide evidence for affordable HCV treatment options in Vietnam using locally produced drugs

03

Conditions studied

  • Chronic Hepatitis C

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with chronic .
  • Age 18-65 years.
  • No previous treatment with interferon or peginterferon.
  • HCV RNA serum baseline >80 IU/mL.
  • Compensated liver disease (total \<25.6 µmol/L, \<1.5, serum albumin >3.4 g/dL, no ascites or hepatic encephalopathy).
  • Normal hematological and biochemical parameters ( >12 g/dL for males, >11 g/dL for females; neutrophils >1500 cells/µL; >75,000 cells/µL; serum creatinine \<1.5 mg/dL or \<132 µmol/L).

Exclusion criteria

Exclusion Criteria:

  • Depression.
  • hepatitis or other autoimmune diseases.
  • Unstable hyperthyroidism or hypothyroidism.
  • Severe medical conditions (e.g., hypertension, congestive heart failure, angina, uncontrolled diabetes, ).
  • Decompensated cirrhosis.
  • Co-infection with or .
  • Pregnant women or those unwilling to use effective .
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Pegnano (Peginterferon alfa-2a)

    Drug: Peginterferon Alfa-2A · Drug: Ribavirin Oral Product

Interventions

  • 180 mcg, subcutaneous injection, once weekly

    Also known as: Pegnano (Peginterferon alfa-2a)

  • 15 mg/kg daily, oral (1200 mg/day for body weight \>80 kg)

    Also known as: Barivir

06

What researchers measure

Primary outcomes

  1. Sustained Virological Response (SVR)

    Percentage of patients with undetectable HCV RNA 24 weeks after treatment completion, measured by real-time reverse transcriptase PCR. In this study, the term "undetectable HCV RNA" refers to the absence of detectable Hepatitis C viral RNA in the patient's serum as measured by Real-Time reverse transcriptase PCR. This method exhibits high sensitivity and specificity, enabling the accurate quantification of HCV RNA. An 'undetectable' result indicates that the viral load was below the lower limit of detection of the assay used (negative). Virological responses were assessed at multiple time points, including week 4 (RVR), week 12 (cEVR), at the end of treatment (EOT), and 12 or 24 weeks post-treatment (SVR12, SVR24). Achieving 'undetectable HCV RNA' at these points was used to determine the effectiveness of the therapy. In this study, SVR and SVR24 are interchangeable.

    Time frame: 24 weeks post-treatment

Secondary outcomes

  1. Rapid Virological Response (RVR)

    Percentage of patients with undetectable HCV RNA at week 4, measured by real-time reverse transcriptase PCR. In this study, the term "undetectable HCV RNA" refers to the absence of detectable Hepatitis C viral RNA in the patient's serum as measured by Real-Time reverse transcriptase PCR. This method exhibits high sensitivity and specificity, enabling the accurate quantification of HCV RNA. An 'undetectable' result indicates that the viral load was below the lower limit of detection of the assay used (negative). Virological responses were assessed at multiple time points, including week 4 (RVR), week 12 (cEVR), at the end of treatment (EOT), and 12 or 24 weeks post-treatment (SVR12, SVR24). Achieving 'undetectable HCV RNA' at these points was used to determine the effectiveness of the therapy.

    Time frame: Week 4

  2. Complete Early Virological Response (cEVR)

    Percentage of patients with undetectable HCV RNA at week 12 (in non-RVR patients), measured by real-time reverse transcriptas PCR. In this study, the term "undetectable HCV RNA" refers to the absence of detectable Hepatitis C viral RNA in the patient's serum as measured by Real-Time reverse transcriptase PCR. This method exhibits high sensitivity and specificity, enabling the accurate quantification of HCV RNA. An 'undetectable' result indicates that the viral load was below the lower limit of detection of the assay used (negative). Virological responses were assessed at multiple time points, including week 4 (RVR), week 12 (cEVR), at the end of treatment (EOT), and 12 or 24 weeks post-treatment (SVR12, SVR24). Achieving 'undetectable HCV RNA' at these points was used to determine the effectiveness of the therapy.

    Time frame: Week 12

  3. End of Treatment Response (ETR)

    Percentage of patients with undetectable HCV RNA at the end of treatment, measured by real-time PCR.

    Time frame: End of treatment: 24 weeks for genotypes 2 and 3; 48 weeks for genotypes 1, 4, 5, and 6. For genotypes 1 and 4, extend to 72 weeks if only LVR is achieved. For genotypes 2 and 3, extend to 48 weeks if non-RVR but EVR is present.

  4. Safety (Adverse Events)

    Incidence and severity of clinical and paraclinical adverse events (e.g., anemia, neutropenia, depression), assessed every 4 weeks

    Time frame: Throughout treatment (up to 72 weeks) and 24 weeks post-treatment (up to week 96)

07

Results

Posted Jun 29, 2025

Participant flow

Participant flow — Overall Study
MilestonePegnano (Peginterferon Alfa-2a)
Started100
Completed97
Not completed3

Outcome measures

PrimarySustained Virological Response (SVR)

Percentage of patients with undetectable HCV RNA 24 weeks after treatment completion, measured by real-time reverse transcriptase PCR. In this study, the term "undetectable HCV RNA" refers to the absence of detectable Hepatitis C viral RNA in the patient's serum as measured by Real-Time reverse transcriptase PCR. This method exhibits high sensitivity and specificity, enabling the accurate quantification of HCV RNA. An 'undetectable' result indicates that the viral load was below the lower limit of detection of the assay used (negative). Virological responses were assessed at multiple time points, including week 4 (RVR), week 12 (cEVR), at the end of treatment (EOT), and 12 or 24 weeks post-treatment (SVR12, SVR24). Achieving 'undetectable HCV RNA' at these points was used to determine the effectiveness of the therapy. In this study, SVR and SVR24 are interchangeable.

Time frame:
24 weeks post-treatment
Reported as:
Count of participants · Participants
Sustained Virological Response (SVR)
ParticipantsPegnano (Peginterferon Alfa-2a)
G117
G210
G656
Total83
Statistical analysis
  • Pegnano (Peginterferon Alfa-2a) · Regression, Logistic · p = 0.008 · Odds ratio (or): 6.73 · 95% CI 1.63 to 27.8
SecondaryRapid Virological Response (RVR)

Percentage of patients with undetectable HCV RNA at week 4, measured by real-time reverse transcriptase PCR. In this study, the term "undetectable HCV RNA" refers to the absence of detectable Hepatitis C viral RNA in the patient's serum as measured by Real-Time reverse transcriptase PCR. This method exhibits high sensitivity and specificity, enabling the accurate quantification of HCV RNA. An 'undetectable' result indicates that the viral load was below the lower limit of detection of the assay used (negative). Virological responses were assessed at multiple time points, including week 4 (RVR), week 12 (cEVR), at the end of treatment (EOT), and 12 or 24 weeks post-treatment (SVR12, SVR24). Achieving 'undetectable HCV RNA' at these points was used to determine the effectiveness of the therapy.

Time frame:
Week 4
Reported as:
Count of participants · Participants
Rapid Virological Response (RVR)
ParticipantsPegnano (Peginterferon Alfa-2a)
G119
G212
G657
SecondaryComplete Early Virological Response (cEVR)

Percentage of patients with undetectable HCV RNA at week 12 (in non-RVR patients), measured by real-time reverse transcriptas PCR. In this study, the term "undetectable HCV RNA" refers to the absence of detectable Hepatitis C viral RNA in the patient's serum as measured by Real-Time reverse transcriptase PCR. This method exhibits high sensitivity and specificity, enabling the accurate quantification of HCV RNA. An 'undetectable' result indicates that the viral load was below the lower limit of detection of the assay used (negative). Virological responses were assessed at multiple time points, including week 4 (RVR), week 12 (cEVR), at the end of treatment (EOT), and 12 or 24 weeks post-treatment (SVR12, SVR24). Achieving 'undetectable HCV RNA' at these points was used to determine the effectiveness of the therapy.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Complete Early Virological Response (cEVR)
ParticipantsPegnano (Peginterferon Alfa-2a)
G124
G213
G663
SecondaryEnd of Treatment Response (ETR)

Percentage of patients with undetectable HCV RNA at the end of treatment, measured by real-time PCR.

Time frame:
End of treatment: 24 weeks for genotypes 2 and 3; 48 weeks for genotypes 1, 4, 5, and 6. For genotypes 1 and 4, extend to 72 weeks if only LVR is achieved. For genotypes 2 and 3, extend to 48 weeks if non-RVR but EVR is present.
Reported as:
Count of participants · Participants
End of Treatment Response (ETR)
ParticipantsPegnano (Peginterferon Alfa-2a)
G122
G213
G662
SecondarySafety (Adverse Events)

Incidence and severity of clinical and paraclinical adverse events (e.g., anemia, neutropenia, depression), assessed every 4 weeks

Time frame:
Throughout treatment (up to 72 weeks) and 24 weeks post-treatment (up to week 96)
Reported as:
Count of participants · Participants
Safety (Adverse Events)
ParticipantsPegnano (Peginterferon Alfa-2a)
Safety (Adverse Events)100

Adverse events

Collected over Throughout treatment (up to 72 weeks) and 24 weeks post-treatment (up to week 96). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pegnano (Peginterferon Alfa-2a)0/100 (0%)0/100 (0%)100/100 (100%)
Most frequent other events
Showing 10 of 18
Most frequent other events
EventPegnano (Peginterferon Alfa-2a)
AlopeciaSkin and subcutaneous tissue disorders78/100
AnorexiaMetabolism and nutrition disorders58/100
SluggishGastrointestinal disorders41/100
InsomniaPsychiatric disorders35/100
ChillGeneral disorders33/100
MyalgiaMusculoskeletal and connective tissue disorders29/100
Mild pyrexia (without use of Paracetamol)General disorders22/100
FatigueGeneral disorders22/100
PruritusSkin and subcutaneous tissue disorders20/100
Moderate Pyrexia (with use of Paracetamol)General disorders19/100

Baseline characteristics

Age, Continuous
Age, Continuous(years)Pegnano (Peginterferon Alfa-2a)
Mean47 ± 11
Sex: Female, Male
Sex: Female, Male(Participants)Pegnano (Peginterferon Alfa-2a)
Female34
Male66
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Pegnano (Peginterferon Alfa-2a)
Weight (kg)
Weight (kg)(kg)Pegnano (Peginterferon Alfa-2a)
Mean62.4 ± 10
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2011 to primary completion in Jan 2013, 22 months.

Results were first posted in Jun 2025, 12 years 5 months after primary completion.

Of 24 phase 4 interventional studies under Hepatitis C, Chronic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 48. This study's 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2025
First posted
Apr 10, 2025
StartActual
Mar 1, 2011
Primary completionActual
Jan 21, 2013
CompletionActual
Mar 1, 2013
Results first posted
Jun 29, 2025
Last update
Jun 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06922643
Lead sponsor
Nanogen Pharmaceutical Biotechnology Joint Stock Company
Responsible party
Sponsor
First posted
Apr 10, 2025
Start date
Mar 1, 2011
Primary completion
Jan 21, 2013
Completion
Mar 1, 2013
Results posted
Jun 29, 2025
Last update
Jun 29, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Peginterferon alfa-2a · Ribavirin

Start the discussion